Medication info

Telmisartan/Rosuvastatin 80/20 mg

Prescription medicationTabletOralExpired
Ingredient · strength
Telmisartan›80mg / 1 tabletRosuvastatin Calcium›20.8mg / 1 tablet
Manufacturer / importer
Youngjin Pharmaceutical Co., Ltd.
Appearance
White oval film-coated tablets
Packaging
30 tablets/box [10 tablets/PTP*3]
Approval status
Expired

MFDS item code 201906984 · Approved 2019.09.30

This product's status changed to Expired on 2025.10.31. It may no longer be sold, so consult a doctor or pharmacist before taking it.

Summary

Main use
Treatment of hypertension, improvement of dyslipidemia, and inhibition of atherosclerosis progression and cardiovascular disease risk
Who takes it
Adults
Adult dose
As a result of a drug interaction study of telmisartan 80mg and rosuvastatin 20mg, the active ingredients in this medicine, in the presence of rosuvastatin, the Cmax of telmisartan was approximately 0.87-fold and its AUC was approximately 1.00-fold; in the presence of telmisartan, the Cmax of rosuvastatin increased approximately 1.71-fold and its AUC increased approximately 1.16-fold. Therefore, when administering this medicine, assess the potential risk due to the increase in rosuvastatin Cmax and monitor patients closely. This medicine is for use in adults only. The dose should be individualized for each patient based on the efficacy and tolerability of each component, telmisartan and rosuvastatin. ○ Telmisartan 1. Essential hypertension Adults: The recommended dose is 40 mg of telmisartan orally once daily; 20 mg once daily may be effective in some patients. If necessary, the dose may be increased to 80 mg once daily. When this medicine is administered concomitantly with a thiazide diuretic such as hydrochlorothiazide, it produces an additional blood pressure-lowering effect. When increasing the dose, the maximum blood pressure-lowering effect is achieved 4 ∼ 8 weeks after starting treatment. 2. Reduction of cardiovascular risk Adults: The recommended dose of this medicine is 80 mg orally once daily. The risk-reduction effect on cardiovascular morbidity and mortality at doses below 80 mg has not been established. When starting treatment with this medicine to reduce cardiovascular risk, blood pressure monitoring is recommended, and appropriate adjustment of antihypertensive agents may be required. 3. Patients with hepatic impairment Administer with caution to patients with mild ∼ moderate hepatic impairment, and do not exceed 40 mg once daily. ○ Rosuvastatin calcium 1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medicine, and should continue it throughout the treatment period. This medicine may be taken at any time of day, with or without food. The initial dose is 5 milligrams once daily. If a greater reduction in LDL cholesterol is needed, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 milligrams once daily, and most patients achieve control at this dose. The maintenance dose should be adjusted as appropriate at intervals of 4 weeks or longer according to LDL cholesterol levels, the treatment goal, and the patient's response, and may be increased to a maximum of 20 milligrams once daily. 2. Elderly patients: No dose adjustment is necessary. 3. Patients with renal impairment: No dose adjustment is necessary in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Particular caution is required when administering this medicine at a dose of 20mg to patients with moderate renal impairment. 4. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer this medicine to patients with active liver disease. 5. Race: Because systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of the 40-milligram dose is contraindicated. 6. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of the 40-milligram dose of this medicine is contraindicated in some of these patients. Patients taking telmisartan and rosuvastatin concomitantly may switch to this medicine (a fixed-dose combination with the same amount of each active ingredient) for convenience.

Ingredients

Manufacturer
Youngjin Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of hypertension, improvement of dyslipidemia, and inhibition of atherosclerosis progression and cardiovascular disease risk

  • Essential hypertension
  • coronary artery disease
  • peripheral artery disease
  • stroke
  • transient ischemic attack
  • clinical evidence of end-organ damage
  • high-risk diabetes
  • primary hypercholesterolemia
  • heterozygous familial hypercholesterolemia
  • mixed dyslipidemia
  • homozygous familial hypercholesterolemia
  • hypercholesterolemia
View approved original text

This medication is designed for patients who need to take Telmisartan and Rosuvastatin simultaneously. Telmisartan is primarily used for the treatment of essential hypertension and helps reduce the risk of myocardial infarction, stroke, and cardiovascular disease deaths in elderly patients with a high risk of cardiovascular disease. Rosuvastatin lowers cholesterol levels in patients with hypercholesterolemia and dyslipidemia and delays the progression of atherosclerosis. Additionally, it is used to reduce the risk of stroke and myocardial infarction in middle-aged and older patients at high risk of cardiovascular disease and surgical vascular interventions. The combination of these two medications effectively manages both hypertension and hyperlipidemia, preventing the occurrence and worsening of cardiovascular diseases.

How to take

Adult dose

As a result of a drug interaction study of telmisartan 80mg and rosuvastatin 20mg, the active ingredients in this medicine, in the presence of rosuvastatin, the Cmax of telmisartan was approximately 0.87-fold and its AUC was approximately 1.00-fold; in the presence of telmisartan, the Cmax of rosuvastatin increased approximately 1.71-fold and its AUC increased approximately 1.16-fold. Therefore, when administering this medicine, assess the potential risk due to the increase in rosuvastatin Cmax and monitor patients closely. This medicine is for use in adults only. The dose should be individualized for each patient based on the efficacy and tolerability of each component, telmisartan and rosuvastatin. ○ Telmisartan 1. Essential hypertension Adults: The recommended dose is 40 mg of telmisartan orally once daily; 20 mg once daily may be effective in some patients. If necessary, the dose may be increased to 80 mg once daily. When this medicine is administered concomitantly with a thiazide diuretic such as hydrochlorothiazide, it produces an additional blood pressure-lowering effect. When increasing the dose, the maximum blood pressure-lowering effect is achieved 4 ∼ 8 weeks after starting treatment. 2. Reduction of cardiovascular risk Adults: The recommended dose of this medicine is 80 mg orally once daily. The risk-reduction effect on cardiovascular morbidity and mortality at doses below 80 mg has not been established. When starting treatment with this medicine to reduce cardiovascular risk, blood pressure monitoring is recommended, and appropriate adjustment of antihypertensive agents may be required. 3. Patients with hepatic impairment Administer with caution to patients with mild ∼ moderate hepatic impairment, and do not exceed 40 mg once daily. ○ Rosuvastatin calcium 1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medicine, and should continue it throughout the treatment period. This medicine may be taken at any time of day, with or without food. The initial dose is 5 milligrams once daily. If a greater reduction in LDL cholesterol is needed, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 milligrams once daily, and most patients achieve control at this dose. The maintenance dose should be adjusted as appropriate at intervals of 4 weeks or longer according to LDL cholesterol levels, the treatment goal, and the patient's response, and may be increased to a maximum of 20 milligrams once daily. 2. Elderly patients: No dose adjustment is necessary. 3. Patients with renal impairment: No dose adjustment is necessary in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Particular caution is required when administering this medicine at a dose of 20mg to patients with moderate renal impairment. 4. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer this medicine to patients with active liver disease. 5. Race: Because systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of the 40-milligram dose is contraindicated. 6. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of the 40-milligram dose of this medicine is contraindicated in some of these patients. Patients taking telmisartan and rosuvastatin concomitantly may switch to this medicine (a fixed-dose combination with the same amount of each active ingredient) for convenience.

Precautions

This medication may cause severe harm to the fetus and newborn during pregnancy, so it must be discontinued immediately if pregnancy is confirmed. It is safer for women who are pregnant, may become pregnant, or are breastfeeding to avoid taking this medication. Patients with severe liver dysfunction, bile secretion issues, or muscle disorders should avoid this medication. Patients with severe kidney impairment or those using certain other medications might also need caution or prohibition during administration. Elderly patients, patients with hyperkalemia, and those with compromised liver function should exercise particular caution when using this medication and require regular blood tests and monitoring. If symptoms such as muscle pain or weakness occur, consult a doctor immediately and evaluate muscle damage indicators if necessary. This medication may affect liver function, making it important to regularly monitor liver function tests both before and during treatment. Low blood pressure, dizziness, and fainting may occur; if these symptoms appear, notify healthcare professionals immediately. This medication may interact with other drugs, so inform a doctor or pharmacist if taking other medications. Be careful while driving or operating dangerous machinery, as drowsiness or dizziness may occur. Keep out of reach of children, and avoid transferring to other containers.

Side effects

Headache, positional dizziness, sleep paralysis, increased blood pressure, decreased blood pressure, hypotension, ALT elevation, dysuria, rhinitis, discomfort in oropharynx, pulmonary disease, unspecified gastrointestinal disease, benign gastrointestinal neoplasm, hemorrhoids, skeletal pain, osteoporosis, sensory impairment, movement disorders, atherosclerosis, frequent urination, tinnitus, hearing loss, bad breath, fatty liver, upper respiratory tract infection, pharyngitis, sinusitis, urinary tract infection, cystitis, sepsis, anemia, thrombocytopenia, eosinophilia, hypersensitivity, anaphylactic reaction, hyperkalemia, hypoglycemia, depression, insomnia, anxiety, syncope, visual disturbances, dizziness, bradycardia, tachycardia, dyspnea, abdominal pain, diarrhea, dyspepsia, abdominal distension, vomiting, abdominal discomfort, dry mouth, abnormal liver function, liver disorder, increased sweating, itching, rash, erythema, angioedema, drug rash, toxic skin rash, eczema, urticaria, myalgia, low back pain, muscle cramps, arthralgia, limb pain, tendon pain, acute renal failure, chest pain, weakness, influenza-like illness, increased serum creatinine, increased serum uric acid, elevated liver enzymes, increased serum CK, decreased hemoglobin, hypoglycemia, angioedema, intravascular volume depletion, hypotension, shock, loss of consciousness, jaundice, anaphylactoid symptoms, interstitial pneumonia, rhabdomyolysis, palpitations, fatigue, nausea, lack of efficacy, facial spasms, paresthesia, paralysis, hyperventilation, pneumonia, flushing, erectile dysfunction, anorexia, arrhythmia, weakness, edema, decreased libido, facial edema, alopecia, conjunctivitis, tinnitus, petechiae, constipation, nausea, pancreatitis, pruritus, rash, urticaria, myopathy, rhabdomyolysis, weakness, polyneuropathy, amnesia, peripheral neuropathy, diarrhea, thrombocytopenia, jaundice, hepatitis, Stevens-Johnson syndrome, drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome, lupus-like syndrome, muscle rupture, arthralgia, immune-mediated necrotizing myopathy, hematuria, edema, depression, sleep disorders, interstitial lung disease, sexual dysfunction, gynecomastia, liver failure, cognitive impairment, myasthenia gravis, ocular myasthenia gravis, headache, dizziness, cough, dyspepsia, myalgia, increased CK, constipation, elevated AST, joint pain, fatigue, numbness, paresthesia, chest discomfort, anorexia, abdominal distension, abnormal liver function tests, syncope, generalized pain, muscle cramps, gout, erectile dysfunction, acute renal failure, oliguria, increased serum creatinine

Not everyone experiences these, and they can vary from person to person.

Storage

Keep this medication in a tightly sealed container to protect against air or moisture. Additionally, store the medication at room temperature, ideally between 1°C and 30°C, away from extreme heat or cold.

Appearance and packaging

Appearance

White oval film-coated tablets

Package unit

30 tablets/box [10 tablets/PTP*3]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.